OTSUKA CILOSTAZOL NDA PREPARATION AIDED BY BIO-MEDICAL SYSTEM'S ECG TESTING, WITH FILING EXPECTED IN SEPT.; CLINICOR CREDITED WITH SUCCESS OF SERONO REBIF TRIAL
Executive Summary
Otsuka's NDA submission for its anti-platelet agent cilostazol for intermittent claudication is being supported by Bio- Medical System's automated electrocardiogram technology, Otsuka Clinical Research Manager Jeffrey Heckman said at an Institute for International Research meeting on contract research organization/industry partnerships in Scottsdale, Arizona, April 14-16.